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higher for all tumor sites than for normal mucosa (primary 
tumor and lymph node metastases p  ! 0.0001, liver metas-
tases p  ! 0.01). Bcl-3 nuclear expression did not differ sig-
nificantly between normal mucosa and tumor; however, nu-
clear expression in primary tumor for each of these compo-
nents was strongly associated with survival: the increase in 
hazard for each 50-point increase in nuclear expression was 
91% for Bcl-3, 66% for p65, and 52% for p50 (all p  ! 0.05). 
 Conclusions: Activation of canonical NF-  B subunits p50 
and p65 as measured by nuclear expression is strongly as-
sociated with survival suggesting NF-  B as a prognostic fac-
tor in this disease. Primary tumor nuclear expression appears 
to be as good as, or better than, metastatic sites at predict-
ing prognosis. Bcl-3 nuclear expression is also negatively as-
sociated with survival and deserves further study in CRC. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 The NF-  B family of transcription factors is com-
prised of homo- or heterodimers of the subunits p50, p52, 
p65 (RelA), RelB, and c-Rel  [1] . The canonical NF-  B 
p50/p65 is the best-studied of the dimers. p50/p65 exists 
in the cytoplasm, and is activated by translocation to the 
nucleus after proteasomal degradation of a natural se-
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 Abstract 
 Purpose: NF-  B is an antiapoptotic transcription factor that 
has been shown to be a mediator of treatment resistance. 
Bcl-3 is a regulator of NF-  B that may play a role in oncogen-
esis. The goal of this study was to correlate the activation 
status of NF-  B and Bcl-3 with clinical outcome in a group of 
patients with metastatic colorectal cancer (CRC).  Methods: 
A retrospective study of 23 patients who underwent surgical 
resection of CRC at the University of North Carolina (UNC). 
Activation of NF-  B was defined by nuclear expression of 
select components of NF-  B (p50, p52, p65) and Bcl-3. Tissue 
microarrays were created from cores of normal mucosa, pri-
mary tumor, lymph node metastases and liver metastases in 
triplicate from disparate areas of the blocks, and an intensity 
score was generated by multiplying intensity (0–3+) by per-
cent of positive tumor cells. Generalized estimating equa-
tions were used to note differences in intensity scores among 
normal mucosa and nonnormal tissues. Cox regression mod-
els were fit to see if scores were significantly associated with 
overall survival.  Results: p65 NE was significantly higher in 
primary tumor and liver metastases than normal mucosa 
(both p  ! 0.01). p50 nuclear expression was significantly 
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questering protein I  B. Upon entering the nucleus, NF-
  B acts as a transcription factor for a large number of 
proteins, a substantial fraction of which are well-de-
scribed antiapoptotic proteins. As such, nuclear localiza-
tion has been used as a surrogate for activation of NF-  B 
for study in archived human tissue samples where the use 
of more accurate measures, such as electromobility gel 
shift assays, are not feasible. NF-  B is important to study 
in solid tumors because of its potential to act downstream 
of a number of oncogenic pathways making it a desirable 
therapeutic target with potential for activity across a 
broad range of cancers.
 The mechanisms by which NF-  B is constitutively ac-
tive in solid malignancies remain an area of active study. 
In rare cases, mutations in NF-  B subunits or transloca-
tions of the atypical I  B protein Bcl-3 result in abnormal 
activation  [2] . Aside from this, NF-  B can be activated in 
a number of ways including cellular stress, DNA damage, 
exposure to TNF, and by activation of various oncogenic 
pathways  [3] . Perhaps the most relevant oncogenic path-
ways of NF-  B interactions from a standpoint of colorec-
tal cancer (CRC) are those between the NF-  B and the 
RAF/MEK/ERK and the PI3 kinase (PI3K)/AKT path-
ways. Importantly, both of these pathways are activated 
by KRAS mutation in CRC  [4] and both are potentially 
targetable by drug therapies. AKT is a central mediator 
of cellular survival that is activated by a number of up-
stream signals including growth factor signals such as 
ERBB signaling  [5] via PI3K and negatively regulated by 
the tumor suppressor PTEN. AKT has been shown to ac-
tivate I  B kinase (IKK) and hence NF-  B in several set-
tings  [6, 7] . Similarly, both HER2 signaling (which occurs 
through RAS) and oncogenic HRAS expression can acti-
vate NF-  B  [5, 8] . It would therefore be useful to know 
whether the correlation between NF-  B and the MAPK 
pathway or the AKT pathway is stronger in CRC.
 Recently it has been suggested that NF-  B activation 
is associated with resistance to therapy in gastrointestinal 
malignancies, most notably in predicting resistance to 
chemoradiation in esophageal cancer  [9] and predicting 
resistance to a combination of irinotecan and cetuximab 
in CRC  [10] . Neither of these studies, however, addressed 
the possibility that NF-  B is a prognostic rather than pre-
dictive marker. Furthermore, the literature on the role of 
NF-  B in disease progression in colorectal neoplasms is 
sparse.
 We therefore embarked on a study with several aims: 
(1) to determine whether p50 and/or p65 nuclear expres-
sion is prognostic in patients with metastatic CRC who 
were treated surgically, (2) to determine which NF-  B 
subunit appears to be more predictive of survival, (3) to 
determine whether there are differences in NF-  B activa-
tion in primary tumors, lymph node metastases and liver 
metastases, and (4) to assess whether NF-  B activation 
correlates more strongly with RAF/MEK/ERK pathway 
activation or AKT activation using antibodies against 
phosphorylated ERK and AKT.
 Methods 
 Tissue Microarray Creation 
 We identified 23 patients with metastatic CRC who had un-
dergone surgical resection for metastatic disease between 1993 
and 2005, and who had at least normal mucosa, primary tumor 
and one metastatic site biopsied or resected. Results of surgery are 
noted in  table 1 . Tissue specimens from normal colorectal mu-
cosa, primary tumor site in colon, lymph node and hepatic me-
tastases were stored in archived paraffin-embedded blocks. A tis-
sue microarray (TMA) was created using fixed and paraffin-em-
bedded tumors and adjacent nonneoplastic colorectal mucosa 
which were cored with a 1-mm needle and inserted into a recipi-
ent paraffin block (Beecher Instruments, Sun Prairie, Wisc., 
USA). Samples from the same tumor were staggered in the array 
and a map was created for later identification of the identity of 
individual cores.
Table 1. Patient characteristics
Age
<50 years 3/23 13%
50–70 years 13/23 57%














Proximal colon 7/23 30.4%





Palliative/not resected 5/23 21.7%
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 Clinical data including survival were abstracted from Univer-
sity of North Carolina (UNC) medical records under an Institu-
tional Review Board-approved protocol. All survival data were 
censored as of the last time of survival data collection in Decem-
ber 2007.
 Immunohistochemistry Staining 
 Antibodies utilized for immunohistochemistry (IHC) are de-
tailed in  table 2 . Briefly, unstained 5-  m-thick sections were 
baked at 60 ° C for 15 min to 1 h. Baked sections were soaked twice 
in fresh xylene for 5 min each, then soaked in 100% ethanol for
3 min and blocked for endogenous peroxidase with 3% hydrogen 
peroxide in methanol for 10 min. Slides were soaked in 95% etha-
nol for 3 min, 70% ethanol for 3 min, rinsed in distilled water, and 
soaked in Dako wash buffer (Dako Cat. No. S3006; Dako, Glos-
trup, Denmark) for 5 min. Slides were then steamed in a Black & 
Decker steamer for 25 min using antigen retrieval buffers (Dako) 
for each primary antibody to be studied ( table 2 ) and then allowed 
to cool for at least 20 min. Sections were transferred to Dako wash 
buffer for 5 min. Endogenous biotin was neutralized by incubat-
ing the slides in a biotin blocking system (Dako Cat. No. X0590) 
for 10 min at room temperature in each of the two solutions. Sec-
tions were then exposed to the primary antibodies at the titers 
specified in  table 2 for 30 min at room temperature. After rinsing 
in Dako wash buffer, slides were incubated with the Dako LSAB2 
biotinylated link for 10 min at room temperature, rinsed in Dako 
wash buffer, and then incubated with the Dako LSAB2 strepta-
vidin-horseradish peroxidase for 10 min at room temperature. 
After additional rinsing in Dako wash buffer, detection of the an-
tibody/antigen complex was visualized using 3,3  -diaminobenzi-
dine for 5 min. Slides were then rinsed in water, lightly coun-
terstained in filtered Mayer’s hematoxylin, rinsed, dehydrated, 
cleared, and mounted. The cells of interest in each core were 
scored for percentage reactivity and signal strength in both the 
cytoplasm and the nuclei. Simultaneously stained normal colorec-
tal mucosa and no primary antibody-stained normal mucosa 
served as negative controls in each experiment.
 Scoring of TMAs 
 One surgical pathologist (W.K.F.) blinded to clinical informa-
tion scored all TMA cores by multiplying the average staining 
intensity seen in a given core on a scale of 0–3+ by the percentage 
of cells that were positive to any degree, creating a range of pos-
sible scores of 0–300. Triplicate cores were staggered in the TMA 
to reduce the chance of staining or interpretive bias, and results 
were averaged among informative cores.
 Statistical Analysis 
 Generalized estimating equations, which account for corre-
lated data, were used to estimate the differences in protein scores 
among normal and nonnormal tissues, and the differences among 
nonnormal tissues. Spearman’s rank correlation coefficient was 
used to describe the strength of association between marker 
scores from the three nonnormal tissues. Bootstrap percentile 
methods were used to compute the p values for these coefficients. 
The Kaplan-Meier method was used to construct the survival 
curves with the scores categorized into four groups: (0, 50), (50, 
100), (100, 200) and (200, 300). The log-rank test was used to com-
pare differences among these survival curves. Cox regression 
models were fit to see if the score for each protein and location 
combination was significantly associated with overall survival. 
Statistical analyses were performed with SAS statistical software 
(SAS Institute Inc, Cary, N.C., USA) and R software (http://www.
r-project.org/).
 Results 
 Primary tumors, lymph node metastases (if positive 
for cancer), liver metastases and normal colonic mucosa 
from 23 patients were examined. Patient characteristics 
are described in  table 1 . Most patients had a synchronous 
disease presentation and the majority had moderately 
differentiated tumors. Nine of 23 patients received oxali-
platin and 20/23 had documented therapy with 5-fluoro-
uracil. Overall median survival for the entire group was 
24 months (95% CI: 18, 60).
 As has been reported in other studies, we found that 
p50 and p65 are more frequently localized to the nucleus, 
and hence considered activated in primary and metastat-
ic CRC when compared with normal mucosa ( fig. 1 ). p65 
nuclear staining was positive (100 or greater) in 7 of 23 
(30%) primary tumors versus 3 of 22 (14%) normal mu-
cosae. The mean staining intensity of p65 was also sig-
nificantly higher for tumor than for normal tissue (p = 
0.001). p50 primary tumor nuclear staining was positive 
at a greater frequency with 18 of 22 (82%) patients posi-
tive, but nuclear reactivity for p50 was also more frequent 
than observed for p65 in normal mucosa with 7 of 22 
Table 2. Antibodies and dilutions used for staining of TMAs
Target Antibody Manufacturer Cat. No. Dilution Positive control 
p50 p50NLS Santa Cruz sc-114NLS 1:100 breast carcinoma, Panc-1 cell block
p65 F-6 Santa Cruz sc-8008 1:1,000 tonsil, Panc-1 cell block
Bcl-3 H-146 Santa Cruz sc-13038 1:50 tonsil
AKT Ser-473 Cell Signaling Systems 736E11 1:25 breast carcinoma and prostate carcinoma
ERK Thr-202/Tyr-204 Cell Signaling Systems D13.14.4E 1:200 breast carcinoma and NSCLC
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(32%) cases positive. The difference in mean staining 
 intensity between primary tumor and normal mucosa 
staining for p50 was also significantly different (p  ! 
0.0001). Representative IHC is depicted in  figure 2 .
 There were no significant differences in nuclear p50 or 
p65 expression between primary and metastatic tumors 
(either nodal or liver metastases,  fig. 1 ), suggesting that 
activation of NF-  B may commonly occur prior to the 
development of distant disease. p52 subunit nuclear stain-
ing, a finding that has been reported in breast  [11] and 
hepatocellular cancers  [12] , was not seen in any of the 
cases in this study.
 Another interesting finding was that p50 and p65 
 nuclear positivity were only weakly correlated (  =
0.27, p = 0.025) suggesting one of several possibilities:
(1) there are false negative results using the p65 antibody, 
(2) there are false positives using the p50 antibody, or (3) 
some tumors preferentially express nuclear p50 homodi-
mers or non-p65 containing heterodimers of p50. These 
questions could not be tested directly given the lack of 
frozen tissue for electrophoretic mobility shift assays.
 Importantly, nuclear expression of both p65 and p50 
was a strong predictor of survival ( fig. 3 ). Cox regression 
modeling revealed that each 50-point increase in tumor 
staining score for P65 was associated with a 66% increase 
in the hazard of death (p = 0.0008), while each 50-point 
increase in p50 nuclear staining was associated with a 
52% increase in the hazard of death (p = 0.024).
 Bcl-3 is a potential activator of p50 and p52 homodi-



































































 Fig. 1. Histograms of nuclear staining 
score of p65, p50 and Bcl-3 in mucosa, pri-
mary tumor, liver and lymph node tissue 
demonstrating differences only between 
tumor (of any site) and normal mucosal 
tissue. 
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heterodimers. In our study, Bcl-3 nuclear expression 
was frequently observed both in normal mucosa and in 
tumor tissue (all p values for differences in expression 
were not significant). Interestingly, however, there was 
a strong association between tumor Bcl-3 nuclear ex-
pression and survival (log-rank p = 0.007) ( fig. 4 a). For 
each 50-point increase in Bcl-3 staining score, a patient’s 
hazard of death nearly doubled (Cox regression
p = 0.002). Increasing Bcl-3 expression in normal mu-
cosa was not associated with survival (Cox regression
p = 0.7) ( fig. 4 b). We also assessed correlation between 
Bcl-3 and the p50 subunit staining; the Spearman’s   
for correlation was 0.29 (p = 0.014) suggestive of a mod-
est correlation. Our interpretation of this finding is that 
a subset of CRC may utilize Bcl-3 overexpression with 
coactivation of p50 homodimers as a mechanism of
NF-  B activation.
 To further elucidate possible mechanistic pathways to 
account for the observed constitutive p50 and/or p65 ac-
tivation we performed IHC for activated (phosphorylat-
ed) forms of AKT and ERK, both of which have been de-
scribed as potential upstream activators of NF-  B in the 
literature. Neither marker was associated with survival in 
our dataset. There was strong correlation between posi-
tivity for phospho-ERK staining and positivity for p65 
and p50 nuclear localization (  for p50 = 0.43, p = 0.0009; 
  for p65 = 0.35, p = 0.009). There was no apparent cor-


















 Fig. 2. Representative stain for p65 representing zero nuclear 
staining ( a ), 2+ nuclear reactivity in 50% of cells (score = 100) ( b ), 
and 3+ nuclear reactivity in 60% of cells ( c ). 
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 Discussion 
 The results of this study demonstrate in a cohort of 
patients with metastatic CRC that NF-  B activation has 
prognostic importance. Frequency of nuclear localiza-
tion of NF-  B was similar in primary and metastatic tu-
mors, suggesting that NF-  B activation generally occurs 
prior to metastatic spread in colon cancer. Recently, it has 
been suggested that NF-  B nuclear expression predicted 
resistance to a combination of irinotecan and cetuximab 
in metastatic CRC  [10] based on examination of p65 
(alone) in a cohort of patients who had all been treated 
with the drug combination. Our study suggests the pos-
sibility that NF-  B was simply prognostic rather than 
predictive of cetuximab response.
 Our findings are consistent with those observed in 
several other solid tumor settings. Zhou et al.  [15] dem-
onstrated that NF-  B activation, particularly DNA bind-
ing by the p50 subunit of NF-  B, could identify a high-
risk subset of ER-positive, primary breast cancers des-
tined for early relapse despite adjuvant endocrine therapy 
with tamoxifen. NF-  B activation has been suggested as 
a predictor of resistance to chemoradiation in esophageal 
cancer  [9] based on a sample of patients who were all 
treated similarly.
 Additional findings of our study may speak to the 
methods by which NF-  B activation is assessed in clini-
cal samples. Both p50 and p65 are measurable by IHC, 
and in spite of the fact that they are presumed to be part 
of a heterodimer, the two appear to be expressed in 
colorectal tumor nuclei at different frequencies. This may 
be secondary to particular performance characteristics 
of the two antibodies in paraffin-embedded tissues, or to 
differences in subunit composition in different tumors. 
Utilization of antibodies to both subunits may be ideal 
until such issues are better elucidated. Additionally, our 
results suggest that primary tumor tissue should be 
equivalent to metastatic tissue in terms of assessing NF-
  B positivity.
 The mechanisms by which NF-  B is constitutively ac-
tive in solid malignancies remain an area of active study. 
NF-  B can be activated in a number of ways including 
cellular stress, DNA damage, exposure to TNF, and by 
activation of certain oncogenic pathways  [3] . Perhaps the 
most relevant oncogenic pathway/NF-  B interactions in 
CRC are those between the NF-  B and the RAF/MEK/
ERK and the PI3K/AKT pathways. This is because both 
pathways are frequently active in CRC via mutation of 
pathway elements including KRAS, BRAF, and PI3KCA 
 [16] .
 AKT has been shown to activate IKK and hence NF-
  B in several settings  [6, 17] . Both HER2 signaling and 
oncogenic HRAS expression can activate NF-  B  [5, 6, 8, 
17] . Madrid et al.  [18]  have also shown that oncogenic H-
RAS requires PI3K and AKT to stimulate the transcrip-
tional activity of NF-  B. Activated PI3K and AKT stimu-
late NF-  B-dependent transcription by stimulating 
transactivation domain 1 of the p65 subunit rather than 
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 Fig. 3. Kaplan-Meier plot of overall survival based on p65 ( a ) and p50 ( b ) IHC score by quartiles in primary 
tumor tissue. 
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er than the cytoplasm as a co-activator of NF-  B. Bcl-3 
has been demonstrated to act as an activator of p50 and 
p52 homodimers   [12] and appears frequently in breast 
and hepatocellular carcinomas. The presence of Bcl-3 
and p50 together in the nucleus suggests that this mecha-
nism is active in a fraction of CRC, and could potentially 
help to explain the discordance between p50 and p65 pos-
itivity that was noted in our study.
 The main limitations of our study are sample size and 
heterogeneity of metastatic presentation. Because one of 
the main goals of the study was to examine several tumor 
sites and several markers all in triplicate, we limited the 
number of patients examined to keep the number of eval-
uation points to a manageable number for one patholo-
gist. The need to find patients with multiple tumor sites 
available to assay also limited the number of patients eli-
gible for analysis. The magnitude of survival difference 
given this small sample size was large; this, however, sug-
gests it would now be important to evaluate NF-  B ex-
pression in a dataset where patients did or did not receive 
an anti-EGFR agent to clarify whether there are both 
prognostic and predictive, or just prognostic implications 
of NF-  B activation. We would propose the use of an an-
tibody against p50 for such a study based on our results. 
In the meantime, we also recently validated the prognos-
tic implications of NF-  B in 70 samples from patients 
with nonmetastatic primary rectal carcinoma in a sepa-
rate study  [21] . 
inducing NF-  B nuclear translocation via I  B degrada-
tion. In our patient sample and within the confines of as-
say by IHC we were not able to detect an association be-
tween positivity for AKT activation and nuclear positiv-
ity for either p65 or p50.
 On the other hand, we did identify a correlation be-
tween phospho-ERK staining and both p65 and p50 nu-
clear positivity suggesting that ERK activation may be an 
important determinant of NF-  B activation status in 
CRC. It has been shown that RAS enhances NF-  B tran-
scriptional activity through an RAF-dependent signaling 
pathway that utilizes p38 MAP kinase  [19] . It is likely that 
oncogenic RAF enhances NF-  B transcriptional activity 
through an autocrine feedback loop using the MEK/ERK 
pathway. In a previous work by Norris and Baldwin  [19] , 
conditioned medium from RAF-transformed cells acti-
vated NF-  B transcriptional activity when added to pa-
rental cells. Also recent work has shown that oncogenic 
RAF activates NF-  B in HEK293 cells through an auto-
crine loop that activates SAPK  [20] . Our results support 
that the RAF/MEK/ERK pathway could be a principal 
driver of NF-  B activation in CRC, a hypothesis that will 
be testable in studies of RAF or MEK inhibitors in BRAF 
mutant CRC.
 Lastly, Bcl-3 is an oncogenic regulator of NF-  B activ-
ity that has not been studied in human CRC samples to 
our knowledge. Our study suggests that Bcl-3 may be im-
portant in CRC and should be studied further. Bcl-3 is an 
atypical I  B family member that acts in the nucleus rath-
 Fig. 4.  a Kaplan-Meier plot of overall survival based on Bcl-3 IHC score by quartiles in primary tumor tissue. 
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 In summary, this study provides evidence that NF-  B 
could be an important prognostic marker in CRC and 
should be studied further in a larger sample of patients. 
The continued study of mechanisms of NF-  B activation 
in colon cancer and the study of therapeutic targeting of 
NF-  B should remain a priority. Lastly, Bcl-3’s role in 
CRC and other solid malignancies needs to be further 
defined both in the laboratory and in the clinic.
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